Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications
- 1 March 2000
- journal article
- research article
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 15 (3) , 242-247
- https://doi.org/10.1002/(sici)1099-1166(200003)15:3<242::aid-gps110>3.0.co;2-7
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of alzheimer's diseaseClinical Therapeutics, 1998
- Donepezil Improves Cognition and Global Function in Alzheimer DiseaseA 15-Week, Double-blind, Placebo-Controlled StudyArchives of internal medicine (1960), 1998
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998
- RivastigmineDrugs & Aging, 1998
- Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's diseaseLife Sciences, 1996
- Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's DiseaseJAMA, 1994
- A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's DiseaseNew England Journal of Medicine, 1992
- Medication Use Characteristics in the Elderly: The Iowa 65+ Rural Health StudyJournal of the American Geriatrics Society, 1987
- Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal ForebrainScience, 1982
- NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIESBrain, 1976